Werewolf Therapeutics, Inc. (HOWL)
Largest Insider Buys in Sector
HOWL Stock Price History Chart
HOWL Stock Performance
About Werewolf Therapeutics, Inc.
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule for the treatment of advanced solid tumors; and WTX-330, a …
Insider Activity of Werewolf Therapeutics, Inc.
Over the last 12 months, insiders at Werewolf Therapeutics, Inc. have bought $0 and sold $0 worth of Werewolf Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Werewolf Therapeutics, Inc. have bought $75.84M and sold $40,242 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,853,000 shares for transaction amount of $4.1M was made by RA CAPITAL MANAGEMENT, L.P. (director) on 2023‑01‑06.
List of Insider Buy and Sell Transactions, Werewolf Therapeutics, Inc.
| 2023-01-06 | director | 1.85M 5.9218% | $2.21 | $4.1M | +17.33% | |||
| 2021-12-15 | Sale | Chief Operating Officer | 3,000 0.0157% | $13.41 | $40,242 | -65.47% | ||
| 2021-06-16 | 9,285 0.0512% | $13.37 | $124,140 | +0.29% | ||||
| 2021-06-15 | 7,958 0.0452% | $12.95 | $103,056 | +6.61% | ||||
| 2021-06-14 | 306,055 1.727% | $12.75 | $3.9M | +7.62% | ||||
| 2021-05-04 | 10 percent owner | 245,000 1.3777% | $16.00 | $3.92M | -12.48% | |||
| 2021-05-04 | 150,799 0.848% | $16.00 | $2.41M | -12.48% | ||||
| 2021-05-04 | 1.72M 9.6439% | $16.00 | $27.44M | -12.48% | ||||
| 2021-05-04 | 10 percent owner | 125,759 0.7072% | $16.00 | $2.01M | -12.48% | |||
| 2021-05-04 | 10 percent owner | 800,000 4.4986% | $16.00 | $12.8M | -12.48% | |||
| 2021-05-04 | 10 percent owner | 312,500 1.7573% | $16.00 | $5M | -12.48% | |||
| 2021-05-04 | 312,500 1.7573% | $16.00 | $5M | -12.48% | ||||
| 2021-05-04 | 400,000 2.2493% | $16.00 | $6.4M | -12.48% | ||||
| 2021-05-04 | 10 percent owner | 400,000 2.2493% | $16.00 | $6.4M | -12.48% | |||
| 2021-05-04 | 10 percent owner | 250,000 1.4058% | $16.00 | $4M | -12.48% | |||
| 2021-05-04 | 10 percent owner | 475,000 2.671% | $16.00 | $7.6M | -12.48% | |||
| 2020-12-23 | 15.88M – | $0 | $0 | |||||
| 2020-12-23 | 7.6M – | $0.46 | $3.5M | |||||
| 2020-12-23 | 7.12M – | $8.00 | $56.97M |
Insider Historical Profitability
| GADICKE ANSBERT | 10 percent owner | 6672183 15.2674% | $2.41 | 1 | 0 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | director | 5701056 13.0452% | $2.41 | 5 | 0 | +3.88% |
| EVNIN LUKE | 4284172 9.8031% | $2.41 | 2 | 0 | <0.0001% | |
| MPM BioVentures 2014, L.P. | 10 percent owner | 3187998 7.2948% | $2.41 | 1 | 0 | <0.0001% |
| Flynn James E | 10 percent owner | 2552787 5.8413% | $2.41 | 1 | 0 | <0.0001% |
Institutional Investor Ownership
| RA Capital Management, L.P. | $39.82M | 14.14 | 6.14M | 0% | +$0 | 0.04 | |
| MPM Asset Management LLC | $27.76M | 9.86 | 4.28M | 0% | +$0 | 11.32 | |
| PFM Health Sciences | $19.48M | 6.92 | 3.01M | -13.3% | -$2.99M | 0.54 | |
| Adage Capital Partners Gp L L C | $19.44M | 6.91 | 3M | -1.11% | -$218,123.28 | 0.04 | |
| Bioimpact Capital Llc | $15.47M | 5.5 | 2.39M | 0% | +$0 | 2.51 |